BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Queensland Health

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,982,283

« Back to Dashboard

Which drugs does patent 6,982,283 protect, and when does it expire?

Patent 6,982,283 protects AMITIZA and is included in one NDA. There has been one Paragraph IV challenge on Amitiza.

This patent has twenty patent family members in eighteen countries.

Summary for Patent: 6,982,283

Title:Method for treating drug-induced constipation
Abstract: Provided is a method for treating drug-induced constipation comprising a step of administering an effective amount of a 15-keto-prostaglaindin compound to a subject suffering from drug-induced constipation or a subject having a strong possibility of suffering from it. According to the present invention, a strong antagonistic action against drug-induced constipation can be obtained without substantially losing the main effect of the drug.
Inventor(s): Ueno; Ryuji (Montgomery, MD)
Assignee: Sucampo AG (Zug, CH)
Application Number:10/135,397
Patent Claim Types:
see list of patent claims

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sucampo Pharma LlcAMITIZAlubiprostoneCAPSULE;ORAL021908-001Jan 31, 2006RXYesYes► Subscribe► SubscribeMETHOD FOR TREATING OPIOID-INDUCED CONSTIPATION► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,982,283

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Norway20034864► Subscribe
MexicoPA03010019► Subscribe
South Korea100886598► Subscribe
South Korea20040008168► Subscribe
Japan4332353► Subscribe
Japan2004527567► Subscribe
Spain2282408► Subscribe
European Patent Office1392318► Subscribe
Denmark1392318► Subscribe
Germany60218451► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Express Scripts
US Department of Justice
Queensland Health
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: